Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 193Carcinoma, Non-Small-Cell Lung 160Ovarian Neoplasms 96Lung Neoplasms 58Fallopian Tube Neoplasms 57Neoplasms 50Triple Negative Breast Neoplasms 36Neoplasm Metastasis 36Esophageal Neoplasms 22Carcinoma, Ovarian Epithelial 22Parkinson Disease 4, Autosomal Dominant Lewy Body 21Stomach Neoplasms 20Squamous Cell Carcinoma of Head and Neck 20Head and Neck Neoplasms 19Endometrial Neoplasms 19Adenocarcinoma of Lung 17Melanoma 15Breast Neoplasms, Male 15Urinary Bladder Neoplasms 13Carcinoma 12Uterine Cervical Neoplasms 11Recurrence 11Carcinoma, Squamous Cell 11Brenner Tumor 11Adenocarcinoma Of Esophagus 10Small Cell Lung Carcinoma 9Peritoneal Neoplasms 9Esophageal Squamous Cell Carcinoma 9Adenocarcinoma, Bronchiolo-Alveolar 9Prostatic Neoplasms 8

Interventions

talimogene laherparepvec 1Surgical Procedures, Operative 1Sentinel Lymph Node Biopsy 1Pemetrexed 1Paclitaxel 1Mastectomy, Subcutaneous 1Mammaplasty 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Ductal × Paclitaxel × Clear all
NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
50 enrolled 12 charts
Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡